GALECTIN THERAPEUTICS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, 30071
Mailing Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, 30071
Phone
678-620-3186
Fiscal Year End
1231
EIN
043562325
Financial Overview
FY2025
$17.72M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 31, 2026 | View on SEC |
| 3 Initial insider ownership report | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | March 17, 2026 | View on SEC |
| 8-K Current report of material events | March 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 9, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 22, 2026 | View on SEC |
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 21, 2026 | View on SEC |
Annual Reports
10-K
March 31, 2026
- U.S. patient subgroup in NAVIGATE trial showed a 68% reduction in new esophageal varices.
- Belapectin demonstrated a strong safety profile with no significant increase in serious health issues.
Insider Trading
STRONG SELL
7 insiders
44 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.